期刊文献+

前列地尔联用低分子量肝素治疗老年骨折非大面积肺栓塞疗效观察 被引量:7

Therapeutic Effect of Alprostadil Combined With Low Molecular Weight Heparin for Treatment of Non-massive Pulmonary Embolism in Aged Patients With Fracture
下载PDF
导出
摘要 目的:观察前列地尔联用低分子肝素治疗老年骨折后并发非大面积肺栓塞的疗效。方法:老年骨折后并发非大面积肺栓塞的患者62例,随机分成2组。对照组30例予低分子量肝素钠4100U皮下注射,每12h1次,疗程7~14d;治疗组在予低分子量肝素钠的同时予前列地尔脂微球载体制剂。两组患者同时接受动脉血气、血氧饱和度(SaO2)、超声心动图检查。结果:治疗组与对照组比较,治疗后PaO2、PaC02、SaO2、PASP、MPAP、RAP、PVR、RVEF水平变化有统计学差异(P〈0.05)。对照组总有效率为66.7%o,治疗组总有效率为90.6%,两组比较差异有统计学意义。结论:采用前列地尔联用低分子量肝素可以有效治疗老年骨折后并发非大面积肺栓塞的患者,且出血风险小。 Objective: To observe the clinical effect of alprostadil combined with low molecular weight heparin for treating non-massive pulmonary embolism in aged patients with fracture. Methods: Sixty two aged patients with fracture suffered with nowmassive pulmonary embolism were divided into two groups randomly. Thirty-cases as control group received low molecular weight heparin(4100 U)subcutaneously once 12 hours for 7 to 14 days. Aged patients in treatment group were injected Alprostadil in lipid microspheres (Lipo-PGE1) besides low molecular weight heparirL Changes of PaO2, PaCO2, SaO2, PASP, MPAP, RAP, PVR, RVEF, LVEF were observed in both group. Results: PaO2, PaCO2, SaO2, PASP, MPAP, RAP, PVR and RVEF were significantly improved in treatment group compared to those of control group (P〈0. 05). The total effective rate in control group and treat ment group was 66. 7% and 90.6%.respectively. There was significant difference between two groups. Conclusion: Aiprostadil combined with low molecuiar weight heparin is more effective in treatment of non massive pulmonary embolism in fractured aged patients and with low risk of bleeding.
机构地区 天津市天津医院
出处 《内科急危重症杂志》 2008年第5期236-238,共3页 Journal of Critical Care In Internal Medicine
关键词 前列地尔 低分子肝素 老年骨折 非大面积肺栓塞 Alprostadil Low molecular weight heparin Aged patients with fracture Non-massive pulmona- ry embolism
  • 相关文献

参考文献8

二级参考文献39

  • 1戴汝平,王辰.重视并进一步规范肺血栓栓塞症的影像学诊断[J].中华结核和呼吸杂志,2005,28(9):577-578. 被引量:10
  • 2邢泉生 李贞福 等.不同径路应用PGE1和PE治疗体外循环术后急性肺高压危象[J].国外医学:心血管疾病分册,2001,28:280-284.
  • 3Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med,2000,132:425-434.
  • 4Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist Bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 2001,358 : 1119-1123.
  • 5Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. Chest,2007,131:395-401.
  • 6Abbas AE, Fortuin FD, Schiller NB, et al. Echocardiographic determination of mean pulmonary artery pressure. Am J Cardiol, 2003,92 : 1373-1376.
  • 7Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol,2003,41 : 1021-1027.
  • 8Cohen H, Chahine C, Hui A, et al. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm,2004, 61:1107-1109.
  • 9Channick RN, Sitbon O, Barst R J, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol, 2004,43 ( 12 Suppl S) :62S-67S.
  • 10Newman JH, Bobbins IM. Exercise training in pulmonary hypertension: implications for the evaluation of drug trials. Circulation ,2006,114 : 1448-1449.

共引文献1894

同被引文献85

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部